BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/9/2026 9:23:54 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-01-16 09:40 |
|
Peer-Review Started |
|
2026-01-16 09:40 |
|
First Decision by Editorial Office Director |
|
2026-01-27 07:27 |
|
Return for Revision |
|
2026-01-27 07:27 |
|
Revised |
|
2026-02-02 07:41 |
|
Publication Fee Transferred |
|
2026-02-05 09:07 |
|
Second Decision by Editor |
|
2026-03-06 02:36 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-06 07:29 |
|
Articles in Press |
|
2026-03-06 07:29 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-07 10:15 |
|
Publish the Manuscript Online |
|
2026-06-09 09:23 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bin Liu, Ning Su, Qing-Shi Lin, Yan-Qin Huang and Shao-Feng Chen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shao-Feng Chen, Associate Chief Pharmacist, Department of Pharmacy, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No. 201 Hubin South Road, Xiamen 361004, Fujian Province, China. csfcby@163.com |
| Key Words |
Sodium-glucose cotransporter 2 inhibitors; Colorectal cancer; mFOLFOX6; Type 2 diabetes mellitus; Survival rate; Dapagliflozin |
| Core Tip |
In this study, we evaluated the addition of the sodium-glucose cotransporter 2 inhibitor dapagliflozin to standard mFOLFOX6 chemotherapy in patients with stage III colorectal cancer and type 2 diabetes mellitus after curative resection. The combination significantly improved glycemic control, reduced carcinoembryonic antigen levels, and enhanced 3-year disease-free survival without increasing severe chemotherapy-related toxicity. These findings suggest that sodium-glucose cotransporter 2 inhibitor may offer dual metabolic and oncological benefits in this high-risk comorbid population, supporting its repurposing as an adjunct to adjuvant chemotherapy. |
| Publish Date |
2026-06-09 09:23 |
| Citation |
Liu B, Su N, Lin QS, Huang YQ, Chen SF. Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes. World J Gastrointest Oncol 2026; 18(6): 117912
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i6/117912.htm |
| DOI |
https://doi.org/10.4251/wjgo.v18.i6.117912 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
